Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon.
about
IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infectionImmunotherapy for tularemiaEffective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigensOuter membrane vesicles displaying engineered glycotopes elicit protective antibodiesMonophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strainRole of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge.Host-adaptation of Francisella tularensis alters the bacterium's surface-carbohydrates to hinder effectors of innate and adaptive immunity.Bronchus-associated lymphoid tissue (BALT) and survival in a vaccine mouse model of tularemia.Mitochondrial ROS potentiates indirect activation of the AIM2 inflammasome.Fc receptor-targeting of immunogen as a strategy for enhanced antigen loading, vaccination, and protection using intranasally administered antigen-pulsed dendritic cellsCharacterization of the O-antigen polymerase (Wzy) of Francisella tularensis.Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis.Mucosal immunization with live attenuated Francisella novicida U112ΔiglB protects against pulmonary F. tularensis SCHU S4 in the Fischer 344 rat modelA mucosal subunit vaccine protects against lethal respiratory infection with Francisella tularensis LVS.Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strainsProtection afforded by heat shock protein 60 from Francisella tularensis is due to copurified lipopolysaccharide.Isolation and mutagenesis of a capsule-like complex (CLC) from Francisella tularensis, and contribution of the CLC to F. tularensis virulence in miceThe role of B cells and humoral immunity in Mycobacterium tuberculosis infectionVaccines against tularemia.Production of anti-LPS IgM by B1a B cells depends on IL-1β and is protective against lung infection with Francisella tularensis LVSLack of in vitro and in vivo recognition of Francisella tularensis subspecies lipopolysaccharide by Toll-like receptorsA MyD88-dependent IFNγR-CCR2 signaling circuit is required for mobilization of monocytes and host defense against systemic bacterial challenge.Downmodulation of vaccine-induced immunity and protection against the intracellular bacterium Francisella tularensis by the inhibitory receptor FcγRIIB.Francisella tularensis Vaccines Elicit Concurrent Protective T- and B-Cell Immune Responses in BALB/cByJ Mice.Coactivating signals for the hepatic lymphocyte gamma interferon response to Francisella tularensisToll-like receptor 2 controls the gamma interferon response to Francisella tularensis by mouse liver lymphocytes.Francisella DnaK inhibits tissue-nonspecific alkaline phosphatase.Activities of Murine Peripheral Blood Lymphocytes Provide Immune Correlates That Predict Francisella tularensis Vaccine EfficacyA conserved and immunodominant lipoprotein of Francisella tularensis is proinflammatory but not essential for virulenceNative outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis.Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia.Tularemia vaccine development: paralysis or progress?Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4.Technical transformation of biodefense vaccines.Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challengeUtilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis.Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis.Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensisIgM in microbial infections: taken for granted?
P2860
Q24631904-44A5C104-5ADF-4F9C-BAD3-F4D732D27AFCQ26864945-1F376DD0-4B79-4644-A912-2B575B355F01Q28474115-6A0F9B36-CD1C-4103-B00A-1746DD33F85EQ28831290-749D92AE-C5DD-4444-874A-163D4C81B58AQ30275022-BB9EFE4A-4E30-4819-BFDC-10A04F38F99FQ30411506-9600E9C6-9D22-4FE0-BD75-D6E75B78ED3EQ30424747-FF792BBA-D679-4343-B9D0-BBA94F77754EQ31027494-356311F4-E3B2-4353-A895-5137E1E6B903Q33618911-9D9095D0-5360-4CF6-9722-26FF3611C383Q34068402-7A446814-B5BB-449B-BB0E-D9397270515CQ34087802-B3EDC8FC-68B8-4B4C-88E5-F0BA31602BE2Q34107308-59049D16-B8A4-4314-9C81-7248C7238D52Q34423341-7DE4C8C1-7C06-426B-9D11-5D7E43DE11B9Q34464553-C563C640-463D-4C45-AF93-E80A70160FAAQ34500312-8E012DAF-87D7-4876-A713-31230E8C2D18Q34740339-FD52D6A3-992A-4070-99F0-02E3A61B2D0CQ34760184-70921617-85E6-499D-873E-CDEE7F252185Q34841347-71DF2B75-2055-4142-A3DE-D944465F5472Q35039807-8E71B5F6-5CA9-4A69-B519-00364ADFC021Q35095362-6511EBE0-1757-4A2C-A9B8-E53738CEF3F1Q35175319-1A36B753-5DDC-404D-8C3E-120EE5327322Q35220354-73B67869-8B64-481C-B817-ACE9120DC8ABQ35348877-35CE67EA-D336-4117-AA05-8EC937738603Q35563406-F9BC70F9-CC7A-4716-AEAC-B9FD3EBDAE80Q35606536-CAFC841D-B26E-4160-B144-EBB2AF13EC65Q35689466-4F9C6594-C9C2-4B7B-B2CA-EB25D0F697ECQ36313863-053F6798-88C5-447E-8C8A-969B62DE0D8BQ36347784-B6C08C65-630A-4241-9563-4D41A6583F8BQ36727982-6BC7F285-0220-41F5-9CA0-6ABC03DC3A56Q36789799-2E24913F-3A34-4D8B-AB7E-6EB3E4982D09Q36804275-AACC7F4F-0B56-4021-B078-92828F8A2547Q36898076-B28D31C5-C514-4513-8FF2-EA6BB1E3E3F1Q36908692-5166DD58-3288-40DC-8C55-57C278C200E2Q37033149-87F98FDB-A0BB-46E2-9D7A-351DEC758EACQ37058898-E3446FDC-240F-43A1-8EBF-C7DEC6F80D0FQ37132733-6C2DF957-918D-4C3D-B2DF-ECC375C79293Q37209029-AED9FF79-8F3D-4032-A409-279C1D6BF2BCQ37287818-67B04BF6-198B-4141-BAE8-B8B9D1DF24CAQ37289261-EB8011F5-FDB9-4F6C-8859-0178BA621DAAQ37524875-2D307CD0-1133-421D-BD95-8F8931EB789B
P2860
Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Purified lipopolysaccharide fr ...... B cells and gamma interferon.
@ast
Purified lipopolysaccharide fr ...... B cells and gamma interferon.
@en
Purified lipopolysaccharide from Francisella tularensis live vaccine strain
@nl
type
label
Purified lipopolysaccharide fr ...... B cells and gamma interferon.
@ast
Purified lipopolysaccharide fr ...... B cells and gamma interferon.
@en
Purified lipopolysaccharide from Francisella tularensis live vaccine strain
@nl
prefLabel
Purified lipopolysaccharide fr ...... B cells and gamma interferon.
@ast
Purified lipopolysaccharide fr ...... B cells and gamma interferon.
@en
Purified lipopolysaccharide from Francisella tularensis live vaccine strain
@nl
P2093
P2860
P1476
Purified lipopolysaccharide fr ...... B cells and gamma interferon.
@en
P2093
K L Elkins
V C Dreisbach
P2860
P304
P356
10.1128/IAI.68.4.1988-1996.2000
P407
P577
2000-04-01T00:00:00Z